Immunoglobulin dose: does infection require a temporary boost?

Immunoglobulin Dose Adjustment During Infection: What the Evidence Actually Says

In my experience running pediatric immunodeficiency cohorts, this is the single most common dosing question I get from both parents and referring physicians: "The child is on IgG replacement, has come down with another cold — should we add an extra infusion, push the next dose forward, or just push through?" It's an intuitively reasonable question, and an empirically difficult one. The honest answer involves pharmacokinetic nuance that doesn't survive simplification into "boost when sick."

Here is what the data actually support, where the gaps are, and how I approach the decision in practice.

What "Standard" Maintenance Dosing Actually Means

The baseline for intravenous immunoglobulin (IVIG) replacement in primary immunodeficiency (PID) — both pediatric and adult — sits in a band of 300–600 mg/kg every 3 to 4 weeks, with most clinicians initiating therapy around 400–500 mg/kg per month and titrating upward based on serum IgG trough levels and, more importantly, the patient's infection history. That last clause matters. Trough IgG is a useful biomarker, but it is not a treatment target in itself; it is a proxy for the underlying goal, which is freedom from recurrent bacterial and viral infections.

This is where the framing of "baseline dose" already starts to mislead families. There is no single canonical number every PID patient should land on. The European and US guidelines I've worked with describe a starting regimen, not a target. Dose escalation to 600 mg/kg, or higher, is appropriate when a child continues to have breakthrough infections or develops chronic suppurative lung disease, regardless of what their trough looks like on paper.

The trough is a thermostat, not a furnace setting. Read it, but treat the infection history, not the number.

Why a "Temporary Boost" Is Rarely the Right Move for Routine Illness

When a child on stable maintenance develops a routine upper respiratory infection, the instinctive impulse — give more Ig — runs into pharmacokinetic reality. Immunoglobulin G has a half-life of roughly three to four weeks in circulation. An extra bolus layered on top of maintenance dosing will transiently elevate serum IgG, but the molecule will redistribute and catabolize on the same timeline as the underlying dose; you are not creating a new steady state, you are temporarily lifting a curve that is already heading back down.

The guidelines are consistent on this point: for recurrent or breakthrough infections, the recommended intervention is to adjust the maintenance dose or target trough long-term, not to graft on temporary, unmonitored acute boosts during every minor illness. The data simply don't show that short-term, ad-hoc boluses during common viral infections produce a measurable clinical benefit. That's an evidence gap, not a proven negative — but in pediatric PID, we generally don't run clinical practice on what we'd like to be true.

There is a secondary concern: hyperviscosity. Jumping the peak serum IgG significantly above a patient's established range carries risk, particularly for children with underlying cardiovascular or renal vulnerability. This is not a hypothetical — thromboembolic events and hemolytic complications are documented adverse events in the post-marketing safety literature for IVIG, and they track with both infusion rate and absolute peak concentration.

When Acute High-Dose Protocols Are Actually Justified

There is, however, a narrow but real category where targeted high-dose Ig protocols are appropriate and clinically defensible. The clearest example is disseminated enterovirus infection in patients with humoral immunodeficiency — a severe complication that can lead to meningoencephalitis, chronic hepatitis, and disseminated skin or organ involvement. For this specific indication, specialized management protocols permit a 2 g/kg IVIG dose layered onto routine maintenance, alongside appropriate antiviral therapy.

That is a very different use case from "the child has a runny nose." A 2 g/kg bolus is roughly four to five times the monthly maintenance dose delivered at once. It is reserved for a defined complication, administered under specialist supervision, and combined with antimicrobial therapy — it does not substitute for it. The framing matters: it's an adjunct in severe disease, not a standing protocol for febrile days.

Subcutaneous IgG Changes the Equation — Steadily

The SCIG data is where the dose-response story gets much sharper. A direct comparison of higher sustained SCIG dosing (mean 213 mg/kg/week) versus traditional SCIG dosing (120 mg/kg/week) showed a meaningful reduction in non-serious infection rates: 2.76 versus 5.18 episodes per year, with corresponding reductions in annual antibiotic days (48.5 vs 72.75 days/year).

The mechanistic point here is that SCIG delivers IgG into a depot that is absorbed steadily, producing relatively flat serum IgG trajectories without the peaks-and-troughs pattern of IVIG. Pushing the weekly SCIG dose upward translates directly into a higher sustained serum IgG, which is what the immune system actually sees day-to-day. This is a long-term maintenance adjustment, not an acute maneuver — but it is, in my reading of the data, the most evidence-supported lever we have for reducing infection burden in inadequately controlled patients.

The implication for families asking about "boosts": if a child on SCIG is having frequent infections, the better and more defensible intervention is to revisit the weekly maintenance dose in consultation with the immunologist, rather than to administer sporadic extra infusions on sick days.

In SCIG, "more" is a steady ramp. In IVIG, "more" is a peak — useful in narrow indications, blunt as a general tool.

Safety Constraints That Don't Get Negotiated

Whether the question is dose escalation or acute boost, the infusion safety envelope is non-negotiable. Standard IVIG administration requires a slow initiation — typically 0.01 mL/kg/min (0.5 mg/kg/min) for the first 10 to 30 minutes — with gradual escalation to a maximum tolerated rate around 0.10 mL/kg/min (5 mg/kg/min) in patients without adverse reaction. These parameters exist because of a well-characterized infusion reaction profile: headache, flushing, hypotension, anaphylactoid events in IgA-deficient patients, and the thromboembolic risk I mentioned above.

When a child is acutely ill at the time of an infusion, this safety envelope tightens further. Fever, dehydration, and active infection can amplify both infusion-related reactions and the hemodynamic stress of the load. Most immunology centers will defer elective infusions and reschedule rather than push through an acute illness — but deferral is a different decision from escalation, and it is worth being explicit about which one is happening and why.

What I Actually Recommend in Practice

When a family or referring physician brings up an extra Ig dose for a sick child on stable maintenance, here is the framework I work through:

First, distinguish the illness category. A routine upper respiratory infection in an otherwise stable child on maintenance is not an indication for acute Ig boosting. Severe specific complications with a known Ig-responsive pathophysiology — primarily disseminated enterovirus, but also immune thrombocytopenia and certain autoimmune cytopenias, which carry their own evidence base outside PID maintenance — may be.

Second, audit the maintenance regimen. If infections are clustering despite a "standard" dose, the right response is rarely a one-off boost. It is usually a structured re-evaluation of the maintenance target — trough IgG, but more importantly, the infection phenotype: how many, what kind, did any require hospitalization, what did the sputum cultures look like, what is the lung imaging showing.

Third, communicate the limits. I tell families directly that immunoglobulin replacement therapy does not eliminate infection risk — it reduces it, and the magnitude of that reduction depends heavily on getting the maintenance dose right for that individual child's pharmacokinetics and exposure profile. No IgG regimen, however aggressive, replaces appropriate antimicrobial therapy during acute bacterial or viral illness.

Fourth, document the unknowns. The honest answer to whether a short, unmonitored extra bolus during a mild illness helps is that we don't have the data. I won't prescribe what I can't defend, and I won't ask a family to spend the time, vein access, and out-of-pocket cost on something whose benefit is unmeasured.

The Sober Verdict

The question "should we boost during infection?" usually encodes a reasonable concern — that the standard regimen isn't doing enough — paired with an intervention — acute dose layering — that the evidence does not specifically support for routine illness. The defensible answers, in order of how often they are actually correct in my cohorts:

1. The maintenance dose needs upward adjustment, sustained, with re-evaluation of trough and infection history over the next 3–6 months. This is the most common resolution when infections persist.

2. The acute illness needs antimicrobial management, with IgG held at its scheduled cadence. This is the right move for the vast majority of routine infections.

3. A targeted, high-dose, specialist-supervised Ig protocol is warranted for a defined severe complication — disseminated enterovirus being the paradigm case in PID.

What I do not recommend is the reflexive, unmonitored extra infusion every time the child has a fever or a cold. It feels active. It is rarely the active intervention the data actually supports. And in pediatric immunodeficiency, the margin between a meaningful dose adjustment and a hyperviscosity-driven adverse event is one worth respecting.